Manuel Schweikle

Nordovo Biosciences AS, operating under the name clexbio, is a pre-clinical stage biotech company based in Oslo, Norway. The Norwegian company is focused on developing next-generation tissue-engineered allogeneic grafts for transplant, using its proprietary platform technologies clex and vivoset. clexbio combines advanced bio-fabrication approaches with its proprietary hydrogel technology clex to create breakthrough solutions for tissue engineering and single-cell techniques. The private company was founded by Manuel Schweikle and Armend G. Håti, with Armend G. Håti serving as CEO since incorporation.

Nordovo Biosciences AS, operating under the name clexbio, is a pre-clinical stage biotech company based in Oslo, Norway. The Norwegian company is focused on developing next-generation tissue-engineered allogeneic grafts for transplant, using its proprietary platform technologies clex and vivoset. clexbio combines advanced bio-fabrication approaches with its proprietary hydrogel technology clex to create breakthrough solutions for tissue engineering and single-cell techniques. The private company was founded by Manuel Schweikle and Armend G. Håti, with Armend G. Håti serving as CEO since incorporation.